---
title: 'Manufacturing Daily Summary: What Happened on November 12, 2026'
headline: Datwyler details packaging controls for EU GMP Annex 1
description: The company says validated washing cuts contaminants in specified FirstLine
  products by at least 99.9%.
url: https://thebench.bio/news/manufacturing/2026-11-12
topic: manufacturing
date: '2026-11-12'
covers:
- '2026-11-12'
date_published: '2026-11-12T12:03:03Z'
date_modified: '2026-11-13T00:03:25Z'
tags:
- Industry
sources: 2
publisher: TheBench.Bio
---

# Manufacturing Daily Summary: What Happened on November 12, 2026

**Datwyler details packaging controls for EU GMP Annex 1**

The company says validated washing cuts contaminants in specified FirstLine products by at least 99.9%.

## Today in brief

Datwyler says its FirstLine products receive a validated wash that reduces contaminants by at least 99.9%. [1] A pharmaphorum commentary argues that certificates of analysis should provide evidence, not serve as sales materials. [2]

## Packaging controls under Annex 1

Datwyler described its primary-packaging controls and supplier evidence for pharmaceutical manufacturers’ contamination-control strategies. [1] The revised EU GMP Annex 1 includes packaging components, supplier approval and outsourced activities in a contamination control strategy. [1]

Datwyler says its ready-to-sterilize and ready-to-use FirstLine products receive a validated wash that lowers contaminants by at least 99.9%. [1] The company says its Middletown site uses paper-free manufacturing areas, with barcodes and scanners instead of paper records. [1]

## Also worth knowing

- A pharmaphorum commentary argues that certificates of analysis should function as evidence rather than sales documents. [2]

## The day in numbers

- **At least 99.9%**: Contaminant reduction Datwyler reports for validated washing of specified FirstLine products. [1]

## Sources

1. [Building Annex 1 readiness into primary packaging](<https://www.pharmaceutical-technology.com/sponsored/building-annex-1-readiness-into-primary-packaging/>), Pharmaceutical Technology, 2026-11-12
2. [A certificate of analysis should be evidence, not a sales document](<https://pharmaphorum.com/rd/certificate-analysis-should-be-evidence-not-sales-document>), pharmaphorum, 2026-11-12

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmaceutical-technology.com/sponsored/building-annex-1-readiness-into-primary-packaging/>
[2]: <https://pharmaphorum.com/rd/certificate-analysis-should-be-evidence-not-sales-document>
